Neurophet said Thursday that it would exhibit Neurophet AQUA AD, a total solution for treating Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2024.

Neurophet AQUA AD is a software that monitors the effectiveness and side effects of prescription anti-amyloid dementia drugs. Neurophet is preparing for medical device certification of Neurophet AQUA AD in major countries, including Korea, the U.S., and Japan.

The Alzheimer's disease treatment market is expected to expand with the introduction of Leqembi (lecanemab) by Japan's Eisai and U.S.’s Biogen as well as Eli Lilly's Kisunla (donanemab), which recently received U.S. Food and Drug Administration (FDA) approval.

However, these therapies are associated with side effects, such as amyloid-related imaging abnormalities (ARIAs), including brain hemorrhage and brain edema, which require patients to undergo regular MRI scans.

Neurophet AQUA AD quantitatively analyzes MRI and PET images to provide all the brain imaging analysis needed to dose anti-amyloid therapies. It determines patient eligibility before dosing, monitors ARIAs, such as cerebral hemorrhage and cerebral edema, during dosing, and analyzes the effectiveness of amyloid beta reduction after dosing.

At the conference, Neurophet will demonstrate Neurophet AQUA AD and introduce Neurophet SCALE PET, a quantitative analysis software for PET imaging that has been updated with key features. Neurophet SCALE PET standardizes the quantitative assessment of amyloid PET images with a centiloid scale.

“AAIC is a gathering of the world's leading experts on Alzheimer's disease to share the latest knowledge, making it the perfect place to unveil Neurophet AQUA AD,” Neurophet CEO Been Jun-kil said. “With the FDA approval of Leqembi and Kisunla, we expect to see an increase in the use of Neurophet AQUA AD's brain image analysis technology.”

The AAIC is an international conference to advance Alzheimer's disease and dementia research and clinical care, which will be held in Philadelphia, U.S., from July 28 to Aug. 1.